Substance / Medication

Rivaroxaban

Overview

Active Ingredient
rivaroxaban
RxNorm CUI
1114195
Labeler: Cardinal Health 107, LLCUpdated: 2026-02-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

XARELTO is contraindicated in patients with: • Warnings and Precautions (5.2) [see] active pathological bleeding • Adverse Reactions (6.2) [see] severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions)

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Peak and trough concentrations of apixaban and rivaroxaban in adult patients: a systematic review and meta-analysis.
Almalbis Christian Andrew, Md Redzuan Adyani, Andrada Chester Paul et al. · J Thromb Haemost · 2025
PMID: 39798921Meta-Analysis
Rivaroxaban vs. Enoxaparin for Preventing Venous Thromboembolism and Wound Complications after Knee Surgery: A Meta-Analysis.
He Shasha, Yin Xiangbao, Xu Yingqi et al. · J Coll Physicians Surg Pak · 2025
PMID: 41058290Meta-Analysis
The routine use of Rivaroxaban as thromboprophylaxis following endovenous thermal ablation.
Bontinis Alkis, Bontinis Vangelis, Giannopoulos Argirios et al. · Vasa · 2025
PMID: 39885704Meta-Analysis
Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review.
Arabloo Jalal, Rezaei Mohammad Ali, Makhtoumi Vahid et al. · Eur J Clin Pharmacol · 2025
PMID: 39714728Meta-Analysis
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy.
Ma Yi, Song Zaiwei, Li Xinya et al. · Clin Pharmacokinet · 2024
PMID: 38460105Meta-Analysis
Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials.
Hsia Judith, Spyropoulos Alex C, Piazza Gregory et al. · Thromb Haemost · 2024
PMID: 37995748Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rivaroxaban (substance)
SNOMED CT
442031002
UMLS CUI
C1739768
RxNorm CUI
1114195
Labeler
Cardinal Health 107, LLC

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.